Tianjin Medical Journal ›› 2024, Vol. 52 ›› Issue (8): 872-876.doi: 10.11958/20231919

• Clinical Research • Previous Articles     Next Articles

Analysis of dyslipidemia associated with myelodysplastic syndrome

SUN Yanwen(), WANG Cong, CHEN Shiliang, ZHANG Ranran()   

  1. Department of Clinical Laboratory, the First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310000, China
  • Received:2023-12-09 Revised:2024-01-11 Published:2024-08-15 Online:2024-08-16
  • Contact: E-mail:1065454627@qq.com

Abstract:

Objective To analyze blood lipid levels in patients with myelodysplastic syndrome (MDS) and further explore the factors associated with abnormal blood lipids. Methods Eighty-eight newly diagnosed MDS patients were selected as the study group, and 100 healthy subjects were selected as the control group. Fasting blood lipid levels, triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (ApoA1) and ApoB were detected before treatment in the study group and the control group. The differences of serum lipid levels in MDS patients with different WHO-MDS classification, modified International Prognostic Score System (IPSS-R) karyotype, risk stratification and TP53 mutation were investigated. The correlation between ApoA1 level and clinical indicators of MDS patients was analyzed, and clinical indicators of different ApoA1 level groups were compared. Results The levels of TC, HDL-C, LDL-C, ApoA1 and ApoB were significantly lower in the study group than those in the control group (P<0.01). There were no significant differences in TG, TC, HDL-C, LDL-C, ApoA1 and ApoB levels between different subgroups. The ApoA1 level was lower in the IPSS-R high-risk stratification group than that of the IPSS-R low-risk stratification group (P<0.05). There were no significant differences in lipid levels between the different karyotype groups. The level of ApoA1 was lower in the TP53 mutant group than that in the non-TP53 mutant group (P<0.05). Correlation analysis showed that ApoA1 level was positively correlated with body mass index (BMI, P<0.05), and negatively correlated with patient age, percentage of bone marrow original cells, IPSS-R karyotype grouping, IPSS-R risk grouping and TP53 gene mutation (P<0.05). The BMI level was lower in the low ApoA1 group than that of the high ApoA1 group (P<0.05). The percentage of bone marrow original cells and TP53 gene mutation rate of MDS patients were higher in the low ApoA1 group than those in the high ApoA1 group (P<0.05). Conclusion The plasma lipid level in MDS patients is significantly lower than that of healthy controls, and levels of ApoA1 varied significantly in different disease states, which may be associated with TP53 gene mutation.

Key words: myelodysplastic syndromes, dyslipidemias, apolipoprotein A-Ⅰ, genes, p53, karyotyping

CLC Number: